Topera lands CE Mark approval in the European Union and 510(k) clearance from the FDA for its FIRMap catheter for use in mapping cardiac arrhythmias.
Topera said it landed a pair of regulatory wins for its FIRMap catheter.
The Palo Alto, Calif.-based medical device company said it won the CE Mark approval in the European Union and 510(k) clearance from the FDA for the device.
Electrograms captured by the FIRMap catheter are mapped by the already-approved RhythmView 3D mapping workstation, providing electrophysiologists with a "dynamic representation" of the heart's electrical activity for the treatment of arrhythmias, according to the press release.
"This FDA clearance and the recently received international CE Marks for both FIRMap and RhythmView represent a series of significant milestones for Topera. With this product now commercially available, we are able to offer our panoramic diagnostic catheter with our next-generation 3D mapping system. We believe this will help us expand our leadership in identifying and defining the discrete sources that sustain complex arrhythmias," CEO Edward Kerslake said in prepared remarks.
Topera reeled in a $25 million Series C round, 1st reported by MassDevice.com, last spring. First-time backer New Enterprise Assoc. led the round, which also included an unnamed "strategic industry partner."
Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-...
Reva Medical begins enrolling patients in Europe for a trial of its Fantom bioresorbable stent.
A subcommittee of the U.S. Senate's powerful Finance Committee holds a hearing on the medical device...
Zimmer Holdings and Biomet find a buyer for the knee and elbow assets they pledged to divest to...